NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Multiple Technology Appraisal (MTA)

TNF-alpha inhibitors for ankylosing spondylitis and axial spondyloarthritis without radiographic evidence of ankylosing spondylitis (including a review of technology appraisal 143 and technology appraisal 233)

Provisional matrix of consultees and commentators

Consultees		Commentators (no right to submit or appeal)
M	anufacturers/sponsors	General
•	AbbVie (adalimumab)	Allied Health Professionals Federation
•	Merck, Sharp & Dohme (golimumab,	 Board of Community Health Councils in
	infliximab)	Wales
•	Pfizer (etanercept)	 British National Formulary
•	UCB Pharma (certolizumab pegol)	Care Quality Commission
		Commissioning Support Appraisals
Patient/carer groups		Service
٠	Action on Pain	 Department of Health, Social Services
•	Afiya Trust	and Public Safety for Northern Ireland
•	Arthritic Association	Healthcare Improvement Scotland
•	Arthritis & Musculoskeletal Alliance	Medicines and Healthcare products
	(ARMA)	Regulatory Agency
•	Arthritis Care	National Association of Primary Care
•	BackCare	National Pharmacy Association
•	Black Health Agency	NHS Alliance
•	Coalition of Ankylosing Spondylitis Patients	NHS Commercial Medicines Unit
		NHS Confederation Section Medicines Concertium
•	Disability Rights UK Equalities National Council	Scottish Medicines Consortium
•	Leonard Cheshire Disability	Comparator manufacturer(s)
•	Muslim Council of Britain	None
•	Muslim Health Network	
•	National Ankylosing Spondylitis	Relevant research groups
	Society	Arthritis Research UK
•	Pain Concern	Chronic Pain Policy Coalition
•	Pain Relief Foundation	Cochrane Musculoskeletal Group
•	Pain UK	MRC Clinical Trials Unit
•	South Asian Health Foundation	National Institute for Health Research
•	Specialised Healthcare Alliance	Pain Relief Foundation
		Research Institute for the Care of Older
Pr	ofessional groups	People
•	Association of Surgeons of Great	 Society for Back Pain Research
	Britain and Ireland	
•	Bone Research Society	Assessment Group
		 National Institute for Health Research

National Institute for Health and Care Excellence

TNF-alpha inhibitors for ankylosing spondylitis and axial spondyloarthritis without radiographic evidence of ankylosing spondylitis (including a review of technology appraisal 143 and technology appraisal 233) Issue date: January 2014 Page 1 of 3

Consultees	Commentators (no right to submit or appeal)
 British Association of Occupational Therapists British Association of Surgical Oncology British Geriatrics Society British Health Professionals in Rheumatology British Institute of Musculoskeletal Medicine British Institute of Musculoskeletal Medicine British Orthopaedic Association British Society for Rheumatology British Society of Rehabilitation Medicine Chartered Society of Physiotherapy College of Occupational Therapists Physiotherapy Pain Association Primary Care Rheumatology Society Royal College of Anaesthetists Royal College of Pathologists Royal College of Physicians Royal College of Surgeons Royal College of Surgeons Royal Society of Medicine United Kingdom Clinical Pharmacy Association Others Department of Health NHS England NHS Oxfordshire CCG NHS Swale CCG 	 Health Technology Assessment Programme NHS Centre for Reviews & Dissemination and Centre for Health Economics –York <u>Associated Guideline Groups</u> National Clinical Guidelines Centre <u>Associated Public Health Groups</u> Public Health England Public Health Wales NHS Trust
Welsh Government	

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

National Institute for Health and Care Excellence

TNF-alpha inhibitors for ankylosing spondylitis and axial spondyloarthritis without radiographic evidence of ankylosing spondylitis (including a review of technology appraisal 143 and technology appraisal 233) Issue date: January 2014 Page 2 of 3

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology are invited to prepare a submission dossier, can respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD). All non-manufacturer/sponsor consultees are invited to prepare a submission dossier respond to consultations on the draft scope, the Assessment Report and the Appraisal Consultation Document. They can nominate clinical specialists and/or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but are not asked to prepare a submission dossier. Commentators are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; Healthcare Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the British National Formulary. All non-manufacturers/sponsors commentator organisations can nominate clinical specialists and patient experts to present their personal views to the Appraisal Committee.

Assessment group

An independent academic group (commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist in the appraisal) prepares an Assessment Report on the health technology (a review of the clinical and cost effectiveness of the technology(ies)) based on a systematic review of the manufacturer/sponsor and non-manufacturer/sponsor submission dossier to the Institute.

National Institute for Health and Care Excellence

TNF-alpha inhibitors for ankylosing spondylitis and axial spondyloarthritis without radiographic evidence of ankylosing spondylitis (including a review of technology appraisal 143 and technology appraisal 233) Issue date: January 2014 Page 3 of 3